



OFFICIAL PUBLICATION OF
THE MINISTRY OF HEALTH,
BRUNEI DARUSSALAM

Brunei International Medical Journal

Volume 14

12 October 2018 (3 Safar 1440H)

ORAL CONSUMPTION OF CAFFEINATED ENERGY DRINKS INCREASES EXPRESSION OF KI-67 BUT DECREASES BRAIN-DERIVED NEUROTROPHIC FACTOR IN THE BRAIN OF RATS.

Anton S. TKACHENKO¹, Galina I. GUBINA-VAKULYCK², Anatolii I. ONISHCHENKO¹, Tatyana V. GORBACH¹, Oksana A. NAKONECHNA¹, Nataliya S. KUFTERINA³, Esmira V. SHEKHOV-TSOVA¹, Maryna O. TKACHENKO⁴

¹Department of Biochemistry, ²Department of Pathological Anatomy, ³Department of Internal and Occupational Diseases, Kharkiv National Medical University, Kharkiv, Ukraine and ⁴Kharkiv Municipal Clinical Hospital N° 27, Kharkiv, Ukraine.

ABSTRACT

Cytotoxic effects of caffeinated energy drinks and their components have previously been reported. **The aim** of this study was to investigate the effect of regular oral consumption of caffeinated energy drinks on the brain, especially on cerebral Ki-67 expression, levels of brain-derived neurotrophic factors and β -nerve growth factor in a rat model. **Materials and methods.** The brain homogenate levels of BDNF and β -NGF were measured in rats fed on a regular diet of caffeinated energy drinks for two months, using commercially available ELISA kits and compared with levels measured in control rats. Ki-67 expression was assessed immunohistochemically to evaluate the proliferation rate of different types of cells in the brain tissue. **Results.** Caffeinated energy drink consumption for two months was associated with the development of histological features of brain edema, significantly increased expression of Ki-67 with BDNF levels significantly reduced by half ($p=0.02$), in brain homogenates compared to control rats. **Conclusions.** Chronic oral consumption of caffeinated energy drinks was associated with significantly reduced BDNF levels and an overexpression of Ki-67 in macroglial cells, endotheliocytes, and ventricular ependymocytes suggesting a proliferative response to neural injury.

Key words: Brain-Derived Neurotrophic Factor, β -Nerve Growth Factor, Caffeine, Energy Drinks, Ki-67 Antigen.

Brunei Int Med J. 2018;14:140-146

Brunei International Medical Journal (BIMJ)

Official Publication of the Ministry of Health, Brunei Darussalam

EDITORIAL BOARD

Editor-in-Chief	William Chee Fui CHONG
Sub-Editors	Vui Heng CHONG Ketan PANDE
Editorial Board Members	Nazar LUQMAN Muhd Syafiq ABDULLAH Alice Moi Ling YONG Ahmad Yazid ABDUL WAHAB Jackson Chee Seng TAN Dipo OLABUMUYI Pemasiri Upali TELISINGHE Roselina YAAKUB Pengiran Khairol Asmee PENGIRAN SABTU Dayangku Siti Nur Ashikin PENGIRAN TENGAH

INTERNATIONAL EDITORIAL BOARD MEMBERS

Lawrence HO Khok Yu (Singapore)	Surinderpal S BIRRING (United Kingdom)
Emily Felicia Jan Ee SHEN (Singapore)	Leslie GOH (United Kingdom)
John YAP (United Kingdom)	Chuen Neng LEE (Singapore)
Christopher HAYWARD (Australia)	Jimmy SO (Singapore)
Jose F LAPENA (Philippines)	Simon Peter FROSTICK (United Kingdom)

Advisor

Wilfred PEH (Singapore)

Past Editors

Nagamuttu RAVINDRANATHAN
Kenneth Yuh Yen KOK

Proof reader

John WOLSTENHOLME (CfBT Brunei Darussalam)

Aim and Scope of Brunei International Medical Journal

The Brunei International Medical Journal (BIMJ) is a six monthly peer reviewed official publication of the Ministry of Health under the auspices of the Clinical Research Unit, Ministry of Health, Brunei Darussalam.

The BIMJ publishes articles ranging from original research papers, review articles, medical practice papers, special reports, audits, case reports, images of interest, education and technical/innovation papers, editorials, commentaries and letters to the Editor. Topics of interest include all subjects that relate to clinical practice and research in all branches of medicine, basic and clinical including topics related to allied health care fields. The BIMJ welcomes manuscripts from contributors, but usually solicits reviews articles and special reports. Proposals for review papers can be sent to the Managing Editor directly. Please refer to the contact information of the Editorial Office.

Instruction to authors

Manuscript submissions

All manuscripts should be sent to the Managing Editor, BIMJ, Ministry of Health, Brunei Darussalam; e-mail: editor-in-chief@bimjonline.com. Subsequent correspondence between the BIMJ and authors will, as far as possible via should be conducted via email quoting the reference number.

Conditions

Submission of an article for consideration for publication implies the transfer of the copyright from the authors to the BIMJ upon acceptance. The final decision of acceptance rests with the Editor-in-Chief. All accepted papers become the permanent property of the BIMJ and may not be published elsewhere without written permission from the BIMJ.

Ethics

Ethical considerations will be taken into account in the assessment of papers that have experimental investigations of human or animal subjects. Authors should state clearly in the Materials and Methods section of the manuscript that institutional review board has approved the project. Those investigators without such review boards should ensure that the principles outlined in the Declaration of Helsinki have been followed.

Manuscript categories

Original articles

These include controlled trials, interventional studies, studies of screening and diagnostic tests, outcome studies, cost-effectiveness analyses, and large-scale epidemiological studies. Manuscript should include the following; introduction, materials and methods, results and conclusion. The objective should be stated clearly in the introduction. The text should not exceed 2500 words and references not more than 30.

Review articles

These are, in general, invited papers, but unsolicited reviews, if of good quality, may be considered. Reviews are systematic critical assessments of

literature and data sources pertaining to clinical topics, emphasising factors such as cause, diagnosis, prognosis, therapy, or prevention. Reviews should be made relevant to our local setting and preferably supported by local data. The text should not exceed 3000 words and references not more than 40.

Special Reports

This section usually consist of invited reports that have significant impact on healthcare practice and usually cover disease outbreaks, management guidelines or policy statement paper.

Audits

Audits of relevant topics generally follow the same format as original article and the text should not exceed 1,500 words and references not more than 20.

Case reports

Case reports should highlight interesting rare cases or provide good learning points. The text should not exceed 1000 words; the number of tables, figures, or both should not be more than two, and references should not be more than 15.

Education section

This section includes papers (i.e. how to interpret ECG or chest radiography) with particular aim of broadening knowledge or serve as revision materials. Papers will usually be invited but well written paper on relevant topics may be accepted. The text should not exceed 1500 words and should include not more than 15 figures illustration and references should not be more than 15.

Images of interest

These are papers presenting unique clinical encounters that are illustrated by photographs, radiographs, or other figures. Image of interest should include a brief description of the case and discussion with educational aspects. Alternatively, a mini quiz can be presented and answers will be posted in a different section of the publication. A maximum of

three relevant references should be included. Only images of high quality (at least 300dpi) will be acceptable.

Technical innovations

This section include papers looking at novel or new techniques that have been developed or introduced to the local setting. The text should not exceed 1000 words and should include not more than 10 figures illustration and references should not be more than 10.

Letters to the Editor

Letters discussing a recent article published in the BIMJ are welcome and should be sent to the Editorial Office by e-mail. The text should not exceed 250 words; have no more than one figure or table, and five references.

Criteria for manuscripts

Manuscripts submitted to the BIMJ should meet the following criteria: the content is original; the writing is clear; the study methods are appropriate; the data are valid; the conclusions are reasonable and supported by the data; the information is important; and the topic has general medical interest. Manuscripts will be accepted only if both their contents and style meet the standards required by the BIMJ.

Authorship information

Designate one corresponding author and provide a complete address, telephone and fax numbers, and e-mail address. The number of authors of each paper should not be more than twelve; a greater number requires justification. Authors may add a publishable footnote explaining order of authorship.

Group authorship

If authorship is attributed to a group (either solely or in addition to one or more individual authors), all members of the group must meet the full criteria and requirements for authorship described in the following paragraphs. One or more authors may take responsibility 'for' a group, in which case the other group members are not authors, but may be listed in an acknowledgement.

Authorship requirement

When the BIMJ accepts a paper for publication, authors will be asked to sign statements on (1) financial disclosure, (2) conflict of interest and (3) copyright transfer. The correspondence author may sign on behalf of co-authors.

Authorship criteria and responsibility

All authors must meet the following criteria: to have participated sufficiently in the work to take public responsibility for the content; to have made substantial contributions to the conception and de-

sign, and the analysis and interpretation of the data (where applicable); to have made substantial contributions to the writing or revision of the manuscript; and to have reviewed the final version of the submitted manuscript and approved it for publication. Authors will be asked to certify that their contribution represents valid work and that neither the manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, except as described in an attachment. If requested, authors shall provide the data on which the manuscript is based for examination by the editors or their assignees.

Financial disclosure or conflict of interest

Any affiliation with or involvement in any organisation or entity with a direct financial interest in the subject matter or materials discussed in the manuscript should be disclosed in an attachment. Any financial or material support should be identified in the manuscript.

Copyright transfer

In consideration of the action of the BIMJ in reviewing and editing a submission, the author/s will transfer, assign, or otherwise convey all copyright ownership to the Clinical Research Unit, RIPAS Hospital, Ministry of Health in the event that such work is published by the BIMJ.

Acknowledgements

Only persons who have made substantial contributions but who do not fulfill the authorship criteria should be acknowledged.

Accepted manuscripts

Authors will be informed of acceptances and accepted manuscripts will be sent for copyediting. During copyediting, there may be some changes made to accommodate the style of journal format. Attempts will be made to ensure that the overall meaning of the texts are not altered. Authors will be informed by email of the estimated time of publication. Authors may be requested to provide raw data, especially those presented in graph such as bar charts or figures so that presentations can be constructed following the format and style of the journal. Proofs will be sent to authors to check for any mistakes made during copyediting. Authors are usually given 72 hours to return the proof. No response will be taken as no further corrections required. Corrections should be kept to a minimum. Otherwise, it may cause delay in publication.

Offprint

Contributors will not be given any offprint of their published articles. Contributors can obtain an electronic reprint from the journal website.

DISCLAIMER

All articles published, including editorials and letters, represent the opinion of the contributors and do not reflect the official view or policy of the Clinical Research Unit, the Ministry of Health or the institutions with which the contributors are affiliated to unless this is clearly stated. The appearance of advertisement does not necessarily constitute endorsement by the Clinical Research Unit or Ministry of Health, Brunei Darussalam. Furthermore, the publisher cannot accept responsibility for the correctness or accuracy of the advertisers' text and/or claim or any opinion expressed.

ORAL CONSUMPTION OF CAFFEINATED ENERGY DRINKS INCREASES EXPRESSION OF KI-67 BUT DECREASES BRAIN-DERIVED NEUROTROPHIC FACTOR IN THE BRAIN OF RATS.

Anton S. TKACHENKO¹, Galina I. GUBINA-VAKULYCK², Anatolii I. ONISHCHENKO¹, Tatyana V. GORBACH¹, Oksana A. NAKONECHNA¹, Nataliya S. KUFTERINA³, Esmira V. SHEKHOVTSOVA¹, Maryna O. TKACHENKO⁴

¹Department of Biochemistry, ²Department of Pathological Anatomy, ³Department of Internal and Occupational Diseases, Kharkiv National Medical University, Kharkiv, Ukraine and ⁴Kharkiv Municipal Clinical Hospital N^o 27, Kharkiv, Ukraine.

ABSTRACT

Cytotoxic effects of caffeinated energy drinks and their components have previously been reported. **The aim** of this study was to investigate the effect of regular oral consumption of caffeinated energy drinks on the brain, especially on cerebral Ki-67 expression, levels of brain-derived neurotrophic factors and β -nerve growth factor in a rat model. **Materials and methods.** The brain homogenate levels of BDNF and β -NGF were measured in rats fed on a regular diet of caffeinated energy drinks for two months, using commercially available ELISA kits and compared with levels measured in control rats. Ki-67 expression was assessed immunohistochemically to evaluate the proliferation rate of different types of cells in the brain tissue. **Results.** Caffeinated energy drink consumption for two months was associated with the development of histological features of brain edema, significantly increased expression of Ki-67 with BDNF levels significantly reduced by half ($p=0.02$), in brain homogenates compared to control rats. **Conclusions.** Chronic oral consumption of caffeinated energy drinks was associated with significantly reduced BDNF levels and an overexpression of Ki-67 in macroglial cells, endotheliocytes, and ventricular ependymocytes suggesting a proliferative response to neural injury.

Key words: Brain-Derived Neurotrophic Factor, β -Nerve Growth Factor, Caffeine, Energy Drinks, Ki-67 Antigen.

INTRODUCTION

Caffeine is considered to be the most widespread stimulant consumed worldwide. ¹ It is known that caffeine improves mood, increases physical and mental performance and endurance. ² In addition to its traditional

sources such as tea and coffee, nowadays caffeine is widely added to various kinds of beverages, including caffeine-containing energy drinks. ^{1, 3, 4} Energy beverages contain much higher concentrations of caffeine in comparison with natural stimulating drinks. It has been reported that some energy drinks may have up to 500 mg of caffeine per serving, whereas the Food and Drug Administration recommends its daily consumption should be limited to 300 mg. ^{3, 5} Due to the diversity of caffeine dietary sources, its consumption has recently skyrocketed. Caffeinated energy

Correspondence: Assistant Professor Anton S. Tkachenko, PhD, Department of Biochemistry, Kharkiv National Medical University, Nauky ave 4, 61022, Kharkiv, Ukraine
Phone: +380 50 109 45 54; Fax number: +380577004132
E-mail: antontkachenko555@gmail.com
ORCID ID: <http://www.orcid.org/0000-0002-1029-1636>

drinks whose popularity has been increasing since 1990s have also contributed to an elevation of caffeine intake, especially among teenagers and adolescents.⁶ The intake of caffeine in high amounts may have adverse effects on the body.^{2, 7} Moreover, besides caffeine, energy beverages usually contain other ingredients, including vitamins, taurine, glucuronolactone, etc. Their combined action and influence of separate constituents on the body have not been fully elucidated.

Cytotoxic effects of energy drinks and their components have been demonstrated in several papers.⁸⁻¹⁰ Regeneration of glial cells is known to be a compensatory reaction in response to injury and neuronal cell death.¹¹ Ki-67 is a widely recognized nuclear cell proliferation marker and its expression is associated with compensatory activation of cell proliferation in response to glia and neuronal cell death.¹² Major neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and β -nerve growth factor (β -NGF) have been shown to promote growth and differentiation of certain neurons and synapses in the central and peripheral nervous systems.^{13,14} These proteins also provide neuroprotective effects against certain insults and decreased levels of BDNF have been reported in neurodegenerative diseases.¹⁵⁻¹⁷ Features of regenerative changes as a result of brain tissue injury by caffeinated energy drinks have not been previously studied.

Thus our study objective is to investigate Ki-67 expression in the brain tissue and neurotrophic factors BDNF and β -NGF levels in brain homogenates in laboratory rats after 2 months of oral consumption of caffeinated energy drinks.

MATERIALS AND METHODS

Description of animals and groups

Three-month-old female WAG rats weighing 180-200 g were provided by the vivarium of

Kharkiv National Medical University. Twenty rats were randomly divided into two groups: experimental (n=10) and control (n=10). Animals from the experimental group orally consumed 'Black' caffeine energy drink (12 ml/kg) containing 320 mg/l of caffeine, guarana extract, taurine, and group B vitamins for two months on a daily basis (except weekends). The control group included animals administered drinking water instead of energy drinks.

Bioethics

All experimental procedures were approved by the Committee of Ethics and Bioethics at Kharkiv National Medical University. We strictly followed the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes and Directive 2010/63/EU on the protection of animals used for scientific purposes adopted on September 22, 2010.

Immunohistochemical study of cell proliferation markers

To assess the rate of proliferation of glial and other cells, we chose a well-characterized proliferation marker Ki-67. It is a nuclear protein expressed in dividing cells only.¹²

As soon as animals were sacrificed strictly 2 months after the beginning of experiment, the brain was isolated and its fragments were fixed in 10% formalin solution. After incubation, formalin-fixed paraffin-embedded tissue blocks were prepared. Then 4- μ m-thick sections were obtained from the paraffin-embedded brain tissues using a microtome. The sections were immunostained with mouse monoclonal antibodies to Ki-67 from *Thermo Fischer Scientific* (UK). After incubation with the primary antibodies to Ki-67, the sections were treated with an anti-(mouse IgG)-horseradish peroxidase conjugate. 3,3'-Diaminobenzidine (DAB) was used for visualization. For histological assessment, 4- μ m-thick sections were obtained and stained with Einarson's galloycyanin-chrome

alum staining.

Preparation of brain tissue homogenates

To determine the content of BDNF and β -NGF, the brain was used to prepare homogenates. It was extracted and placed on ice. Then it was weighed and cut into small pieces. A Potter homogenizer was used to prepare homogenates in an isolation medium (1:10 proportion) during 30 seconds on ice with a glass-teflon gap of 0.2 mm. The isolation medium was composed of 0.25 M sucrose, 0.2 M Tris-HCl, and 1 mM EDTA (pH 7.4). After homogenization the suspension was centrifuged at 3,000 rpm during 10 min. The supernatant obtained as a result was used for quantitative determination of the neurotrophic factors mentioned above.

Determination of levels of neurotrophic factors BDNF and β -NGF in cerebral homogenates

We quantitatively determined levels of BDNF and β -NGF in brain homogenates of animals from both experimental and control groups. To measure BDNF concentrations, we used ELISA kits from *R&D Systems* (Minneapolis, USA). The content of β -NGF was also measured by ELISA using kits developed by *RayBiotech* (Norcross, USA). The corresponding assays were carried out in accordance with manufacturer's instructions in 96-well plates. After the addition of Stop solution, absorbance was measured at once at 450 nm using an Awareness Technology Stat Fax 303 Plus Microstrip Reader (USA). Levels of both BDNF and β -NGF were expressed in pg/ml.

Statistics

We used a "GraphPad Prism 5" application for performing all statistical evaluations. Mann-Whitney U test was used to compare two independent groups of variables. The results were considered statistically significant at $p < 0.05$.

RESULTS

Histological slides stained with Einarson's gallocyanin-chrome alum staining revealed that the brain tissue in rats from the control group was well preserved. Ventricular ependyma and epithelial cells of the choroid plexus were intact. Glial cells were not seen accumulating around the third ventricle. Rats from the experimental group had histological features of edema (Figure 1a) in the brain and were noted to have a periventricular zone of young non-differentiated glial-like cells, which are mainly observed during fetal and early neonatal periods. In addition, neuropil of various brain regions in rats from the experimental group seemed to be less dense compared with the control group, suggesting a decrease in the number of processes both in neurons and macroglia.

Immunohistochemical staining using antibodies to Ki-67 revealed that the amount of Ki-67 positive cells in the brain parenchyma of control animals was low. Ki-67-expressing cells were virtually absent in ventricular ependyma, vascular endothelium, and epithelium of the choroid plexus. Only solitary Ki-67-positive gliocytes were observed (Fig. 1b). However, they were found not in each field of vision. In contrast to the experimental group, the zones of macroglia proliferation were not found in the control animals.

Experimental animals had increased number of Ki-67 labeled gliocytes distributed diffusely in the brain tissue (Fig. 2a, 2b, 2c, 2d). In addition, such cells were found in the periventricular region (Fig. 2a, 2c). Moreover, Ki-67 staining was observed in ventricular ependyma and endothelium of microcirculatory blood vessels (Fig. 2b).

Determination of neurotrophic factors in the brain tissue homogenates showed that the content of BDNF in the brain of experimental animals was significantly reduced compared to control animals ($p=0.02$). Levels




Figure 1: a) Brain of a rat from the experimental group. Signs of brain edema are marked with red arrows. Einarson's galloyanin-chrome alum staining. x 400. b) Brain of a rat from the control group. Single Ki-67-labeled cell is visible. Immunohistochemical reaction with antibodies to Ki-67. x100.

peaked at 243.6 [IQR: 180.8, 351.9] pg/ml in the experimental group against 515.6 [IQR: 396.7-583.1] pg/ml in the control animals (Fig. 3). The difference between concentrations of β -NGF in brain homogenates was not statistically significant ($p=0.33$) with a trend towards its reduction. The levels of β -NGF were 11.78 [95% CI: 11.07-13.07] pg/ml compared to 12.41 [95% CI: 10.41-14.66] pg/ml in control animals (Fig. 4).

DISCUSSION

Histological observations (edema and low neuropil density, i.e. a decrease in the amount of unmyelinated axons, dendrites and glial cell processes) in animals from the ex-

perimental group suggested neurons and glial cells injury leading to cell death and reduction of neuronal and glial cell density, as a result of oral consumption of caffeinated energy drinks. Since neuropil is a synaptically dense area and cognitive functions such as learning and memory require plasticity based on the formation of new synaptic contacts that develop in the neuropil, low neuropil density observed in this study may be accompanied by a decrease in the amount of synapses and the reduced ability to form the new ones, negatively affecting the cognitive function.¹⁸

Zeidán-Chuliá *et al* have demonstrated that major ingredients of caffeinated energy drinks, including caffeine, taurine, and




Figure 2: Brain Ki-67 immunostaining. A) A microslide of the third ventricle of an animal from the experimental group. Strong Ki-67 immunostaining is observed in ventricular ependyma and glial cells of the periventricular space (marked with green arrows). Immunohistochemical reaction with antibodies to Ki-67. x400. B) A fragment of the third ventricle of a rat from the experimental group. Ki-67-expressing gliocytes are marked with green arrows. Immunohistochemical reaction with antibodies to Ki-67. x400. C) A microslide of the third ventricle of a rat from the experimental group. Ki-67-positive ependymal cells and periventricular glial cells can be seen (marked with green arrows). Immunohistochemical reaction with antibodies to Ki-67. x100. D) A microslide of a lateral ventricle of the brain of a rat from the experimental group. Ki-67 is expressed in some ependymocytes, endothelial cells of capillaries (marked with a red arrow), and epithelial cells in the choroid plexus (marked with a green arrow). Immunohistochemical reaction with antibodies to Ki-67. x400.




Figure 3: The content of BDNF in brain tissue homogenates of rats after the oral two-month-long consumption of caffeinated energy drinks is provided. Oral intake of caffeine-containing energy beverages resulted in a decrease in the amount of BDNF in the brain of animals ($p=0.02$).

guarana are cytotoxic to human neuronal cells.¹⁰ It has also been reported that the consumption of caffeinated energy drinks against the background of alcohol intake promotes neuronal cells apoptosis in the hippocampus and temporal cortex of rats.⁹ Bawazir AE showed that three-week-long oral consumption of caffeinated energy drinks at a dose of 3.1 ml/day resulted in cell degeneration and necrosis in the hippocampus.⁸ Ki-67 upregulation in the brain indicates the activation of glia proliferation. Such changes in Ki-67 expression may be due to the increased requirements of glial cells as a result of neuronal cell death.¹⁹ In addition, it is worth noting that Ki-67 overexpression in vascular endothelial cells, which is indicative of their proliferation probably due to the action of caffeinated energy drinks, may indicate their damage and contribute to subsequent higher nonselective permeability of blood-brain barrier composed of these cells, since damage to vascular endothelial cells that form the blood-brain barrier increases its permeability.²⁰ Our findings on the negative impact of caffeinated energy drinks on endothelial cells are consistent with data of other researchers. Worthley MI et al reported that the intake of caffeinated energy drinks by humans was accompanied by the decreased vascular endothelial function.²¹ This may reduce the protective effects of the blood-brain barrier and facilitate the transport of constituents of caffeinated energy drinks to the brain.




Figure 4: Levels of β -NGF in the brain tissue homogenates of rats after the two-month-long consumption of caffeinated energy drinks are shown. Statistically significant changes between two groups were not revealed ($p=0.33$).

Analysis of the content of neurotrophic factors BDNF and β -NGF in the brain tissue homogenates of experimental animals revealed that the prolonged oral intake of caffeinated energy drinks was associated with BDNF deficiency against the background of unaffected β -NGF levels. This suggests that the mechanism of brain injury caused by caffeinated energy drinks may involve reducing BDNF levels, hence reducing the neuroprotective effects as well as reducing neuronal growth and differentiation. BDNF is known to be implicated in learning, memory, and synaptic plasticity.²² Given the low neuropil density described above and BDNF deficiency, we further hypothesize that chronic intake of caffeinated energy drinks affects cognitive functions and BDNF deficiency may play a significant role in realization of caffeinated energy drinks-associated cognitive dysfunctions. Moreover, Lipsky RH and Marini AM demonstrated that BDNF promoted survival of neurons and protected them from damage.²³ Thus, BDNF deficiency may contribute to and facilitate cell death of neurons and macroglia if consumption of caffeinated energy drinks is not stopped, making damage to the brain more and more severe.

Our findings that the long-term oral exposure to caffeinated energy drinks causes Ki67 overexpression and BDNF deficiency in the brain of rats confirmed previous published reports on toxicity effects of caffeinated energy beverages. Translating these results

into clinical practice may require further clinical studies to confirm our hypothesis above regarding the mechanism of adverse effects of caffeinated energy drinks and their components on the nervous system (increased expression of Ki-67 and reduced BDNF levels) in clinical subjects.

CONCLUSION

Thus our study indicated that prolonged two months oral consumption of caffeinated energy drinks in rats was associated with histological evidence of neural injury (brain edema and reduced neuropil density) with overexpression of Ki-67 indicating regeneration of glial cells, ventricular ependymal cells and vascular endothelial cells in response to neuronal injury. In addition, this was observed against a background deficiency of brain-protective BDNF, observed as a result of prolonged consumption of high-energy caffeinated drinks. At present, the consumption of caffeinated energy drinks is increasingly popular among the young and working population, our findings may be clinically relevant to public health professionals in educating regular users of caffeinated energy drinks regarding the health hazards associated with their long-term consumption.

DISCLOSURE

All authors have contributed to the manuscript equally. None of the authors have direct or financial conflicts of interest with this paper and material contained herein.

REFERENCES:

- 1: Persad LAB. Energy drinks and the neurophysiological impact of caffeine. *Frontiers in Neuroscience*. 2011; 5:116. doi:10.3389/fnins.2011.00116. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198027/pdf/fnins-05-00116.pdf>
- 2: Temple JL, Bernard C, Lipshultz SE, Czachor JD, Westphal JA, Mestre MA. The safety of ingested caffeine: a comprehensive review. *Frontiers in Psychiatry*. 2017;8:80. doi:10.3389/fpsy.2017.00080. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445139/pdf/fpsy-08-00080.pdf>
- 3: Richards G, Smith AP. A review of energy drinks and mental health, with a focus on stress, anxiety, and depression. *Journal of Caffeine Research*. 2016;6(2):49-63. doi:10.1089/jcr.2015.0033. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892220/pdf/jcr.2015.0033.pdf>
- 4: Alsunni AA. Energy drink consumption: beneficial and adverse health effects. *International Journal of Health Sciences*. 2015;9(4):468-474. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682602/pdf/ijhs-9-4-468.pdf>
- 5: Reissig CJ, Strain EC, Griffiths RR. Caffeinated energy drinks -- a growing problem. *Drug and alcohol dependence*. 2009; 99(1-3):1-10. doi:10.1016/j.drugalcdep.2008.08.001. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735818/pdf/nihms90556.pdf>
- 6: Goldman RD. Caffeinated energy drinks in children. *Canadian Family Physician*. 2013;59(9):947-948. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771720/pdf/0590947.pdf>
- 7: Wikoff D, Welsh BT, Henderson R et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. *Food Chem Toxicol*. 2017;109(Pt 1):585-648. doi: 10.1016/j.fct.2017.04.002. [Accessed on October 2, 2018]. Full article available at <https://reader.elsevier.com/reader/sd/pii/S0278691517301709?to-ken=5E114FBC6C37701EDE3282F9587146D2A0CEC179E14D9532E86E9E51158A73065297E06B2D017C825EFB612F7C8E7CB1>
- 8: Bawazir AE. Effects of energy drink (Red bull) on some neurotransmitters content and histological structure in the hippocampus region in male albino rats. *Int. J. Pharm. Res. AlliedSci*. 2017;6(2):263-276. [Accessed on October 2, 2018]. PDF available at <http://ijpras.com/vol6-iss2/IJPRAS-2017-6-2-263-276.pdf>
- 9: Díaz A, Treviño S, Guevara J et al. Energy drink administration in combination with alcohol causes an inflammatory response and oxidative stress in the hippocampus and temporal cortex

- of rats. *Oxidative Medicine and Cellular Longevity*. 2016;2016:8725354. doi:10.1155/2016/8725354. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812470/pdf/OMCL2016-8725354.pdf>
- 10: Zeidán-Chuliá F, Gelain DP, Kolling EA et al. Major components of energy drinks (caffeine, taurine, and guarana) exert cytotoxic effects on human neuronal SH-SY5Y cells by decreasing reactive oxygen species production. *Oxidative Medicine and Cellular Longevity*. 2013;2013:791795. doi:10.1155/2013/791795. [Accessed on October 2, 2018]. Article available at <https://www.hindawi.com/journals/omcl/2013/791795/>
 - 11: Gallo V, Deneen B. Glial development: the crossroads of regeneration and repair in the CNS. *Neuron*. 2014;83(2):283-308. doi:10.1016/j.neuron.2014.06.010. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114724/pdf/nihms606082.pdf>
 - 12: Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). *Mol Med Rep*. 2015;11(3):1566-72. doi: 10.3892/mmr.2014.2914. [Accessed on October 2, 2018]. Article available at <https://www.spandidos-publications.com/mmr/11/3/1566>
 - 13: Acheson A, Conover JC, Fandl JP, DeChiara TM, Russell M, Thadani A, Squinto SP, Yancopoulos GD, Lindsay RM. "A BDNF autocrine loop in adult sensory neurons prevents cell death". *Nature*. 1995;374 (6521):450-3. Doi:10.1038/374450a0. PMID 7700353
 - 14: Huang EJ, Reichardt LF. "Neurotrophins: roles in neuronal development and function". *Annual Review of Neuroscience*. 2001;24:677-736. doi:10.1146/annurev.neuro.24.1.677. PMC 2758233. PMID 11520916. [Accessed on October 2, 2018]. Article available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758233/>
 - 15: Scalzo P, Kümmer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. *J Neurol*. 2010;257:540-5.
 - 16: Sohrabji F, Lewis DK. Estrogen-BDNF interactions: implications for neurodegenerative diseases. *Front Neuroendocrinol*. 2006;27:404-14. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828910/pdf/nihms-14581.pdf>
 - 17: Mughal MR, Baharani A, Chigurupati S, et al. Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice. *Hum Mol Genet*. 2011;20:659-69. [Accessed on October 2, 2018]. PDF available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024043/pdf/ddq512.pdf>
 - 18: Escobar G, Fares T, Stepanyants A. Structural plasticity of circuits in cortical neuropil. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2008;28(34):8477-8488. doi:10.1523/JNEUROSCI.2046-08.2008. [Accessed on October 2, 2018]. PDF is available at <http://www.jneurosci.org/content/jneuro/28/34/8477.full.pdf>
 - 19: Wharton SB, Williams GH, Stoeber K et al. Expression of Ki67, PCNA and the chromosome replication licensing protein Mcm2 in glial cells of the ageing human hippocampus increases with the burden of Alzheimer-type pathology. *Neurosci Lett*. 2005;22-29;383(1-2):33-8.
 - 20: Won SM, Lee JH, Park UJ, Gwag J, Gwag BJ, Lee YB. Iron mediates endothelial cell damage and blood-brain barrier opening in the hippocampus after transient forebrain ischemia in rats. *Experimental & Molecular Medicine*. 2011;43(2):121-128. doi:10.3858/emmm.2011.43.2.020. [Accessed on October 2, 2018]. PDF is available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047193/pdf/emm-43-121.pdf>
 - 21: Worthley MI, Prabhu A, De Sciscio P, Schultz C, Sanders P, Willoughby SR. Detrimental effects of energy drink consumption on platelet and endothelial function. *Am J Med*. 2010;123(2):184-7. doi: 10.1016/j.amjmed.2009.09.013.
 - 22: Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI. The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease. *Aging and Disease*. 2015;6(5):331-341. doi:10.14336/AD.2015.0825. [Accessed on October 2, 2018]. PDF is available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567216/pdf/ad-6-5-331.pdf>
 - 23: Lipsky RH, Marini AM. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. *Ann N Y Acad Sci*. 2007;1122:130-43.
-